BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15809899)

  • 1. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.
    Tarr PE; Taffé P; Bleiber G; Furrer H; Rotger M; Martinez R; Hirschel B; Battegay M; Weber R; Vernazza P; Bernasconi E; Darioli R; Rickenbach M; Ledergerber B; Telenti A;
    J Infect Dis; 2005 May; 191(9):1419-26. PubMed ID: 15809899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between plasma lipid parameters and APOC3 genotypes in Brazilian subjects: effect of gender, smoking and APOE genotypes.
    Fiegenbaum M; de Andrade FM; Hutz MH
    Clin Chim Acta; 2007 May; 380(1-2):175-81. PubMed ID: 17367769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.
    Bard JM; Lassalle R; Capeau J; Bach-Ngohou K; Nazih-Sanderson F; Rémy G; Reynes J; Ecobichon JL; Savès M; Raffi F;
    Antivir Ther; 2006; 11(3):361-70. PubMed ID: 16759053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study.
    Rotger M; Bayard C; Taffé P; Martinez R; Cavassini M; Bernasconi E; Battegay M; Hirschel B; Furrer H; Witteck A; Weber R; Ledergerber B; Telenti A; Tarr PE;
    Circ Cardiovasc Genet; 2009 Dec; 2(6):621-8. PubMed ID: 20031643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.
    Arnedo M; Taffé P; Sahli R; Furrer H; Hirschel B; Elzi L; Weber R; Vernazza P; Bernasconi E; Darioli R; Bergmann S; Beckmann JS; Telenti A; Tarr PE;
    Pharmacogenet Genomics; 2007 Sep; 17(9):755-64. PubMed ID: 17700364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3 -455T>C polymorphisms on the susceptibility to diabetic nephropathy.
    Ng MC; Baum L; So WY; Lam VK; Wang Y; Poon E; Tomlinson B; Cheng S; Lindpaintner K; Chan JC
    Clin Genet; 2006 Jul; 70(1):20-8. PubMed ID: 16813599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications.
    Tarr PE; Telenti A
    Antivir Ther; 2007; 12(7):999-1013. PubMed ID: 18018758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of the epsilon 2 allele of APOE gene to hypertriglyceridemia and to early-onset alcoholic cirrhosis.
    Hernández-Nazará ZH; Ruiz-Madrigal B; Martínez-López E; Roman S; Panduro A
    Alcohol Clin Exp Res; 2008 Apr; 32(4):559-66. PubMed ID: 18241317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The APOC3 SstI polymorphism is weakly associated with sporadic Alzheimer's disease in a Chinese population.
    Sun Y; Shi J; Zhang S; Tang M; Han H; Guo Y; Ma C; Liu X; Li T
    Neurosci Lett; 2005 Jun; 380(3):219-22. PubMed ID: 15862889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced mortality and CD4 cell loss among carriers of the interleukin-10 -1082G allele in a Zimbabwean cohort of HIV-1-infected adults.
    Erikstrup C; Kallestrup P; Zinyama-Gutsire RB; Gomo E; Butterworth AE; Pedersen BK; Ostrowski SR; Gerstoft J; Ullum H
    AIDS; 2007 Nov; 21(17):2283-91. PubMed ID: 18090276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin.
    Campalani E; Allen MH; Fairhurst D; Young HS; Mendonca CO; Burden AD; Griffiths CE; Crook MA; Barker JN; Smith CH
    Br J Dermatol; 2006 Feb; 154(2):345-52. PubMed ID: 16433808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the APOC3 Sst I SNP on fasting triglyceride levels in men heterozygous for the LPL P207L deficiency.
    Garenc C; Couillard C; Laflamme N; Cadelis F; Gagné C; Couture P; Julien P; Bergeron J
    Eur J Hum Genet; 2005 Oct; 13(10):1159-65. PubMed ID: 16015281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.
    Rimland D; Guest JL; Hernández I; Del Rio C; Le NA; Brown WV
    HIV Med; 2005 Sep; 6(5):326-33. PubMed ID: 16156880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effects of apoE-CI-CII cluster and LDL-R gene polymorphisms on chromosome 19 and coronary artery disease risk.
    Wang C; Zhou X; Ye S; Han D; Tan X; Zheng F; Shi Q
    Int J Hyg Environ Health; 2006 May; 209(3):265-73. PubMed ID: 16459141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of genetic risk for dyslipidemia.
    Yamada Y; Matsuo H; Warita S; Watanabe S; Kato K; Oguri M; Yokoi K; Metoki N; Yoshida H; Satoh K; Ichihara S; Aoyagi Y; Yasunaga A; Park H; Tanaka M; Nozawa Y
    Genomics; 2007 Nov; 90(5):551-8. PubMed ID: 17919884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy.
    Zanone Poma B; Riva A; Nasi M; Cicconi P; Broggini V; Lepri AC; Mologni D; Mazzotta F; Monforte AD; Mussini C; Cossarizza A; Galli M;
    AIDS; 2008 Sep; 22(14):1769-78. PubMed ID: 18753860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
    Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study.
    Haas DW; Geraghty DE; Andersen J; Mar J; Motsinger AA; D'Aquila RT; Unutmaz D; Benson CA; Ritchie MD; Landay A;
    J Infect Dis; 2006 Oct; 194(8):1098-107. PubMed ID: 16991084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.